Dna vaccine composition comprising hepatitis virus b-derived mutant molecule and pathogen- or tumor-associated antigen molecule and use thereof

Abstract

The present disclosure relates to: a DNA vaccine including a mutant molecule derived from a hepatitis B virus and either an antigen molecule of a pathogen or a tumor-associated antigen protein; and use of the DNA vaccine as a composition for preventing or treating a pathogenic infection or a tumor. According to a vaccine composition of an aspect, due to the inclusion of the mutant molecule derived from a hepatitis B virus, humoral immunity and cellular immunity are significantly activated compared to the existing DNA vaccines, and thus the vaccine composition can be utilized as a vaccine for preventing or treating a pathogen infection, such as a viral or bacterial infections or a tumor.

Dependencies are inferred from the claim text.